Research Insights
Evidence-based analysis of peptide research. Research digests unpack landmark studies; trend reports surface cross-peptide patterns; evidence briefs deliver fast reads on single questions.
Eating Enough Protein — and Training Hard Enough — on GLP-1s
A San Raffaele study tracking 332 adults found that GLP-1 users consume just 0.6 g/kg/day of protein — 88% fall below even conservative guidelines. Here's what the muscle-loss data actually shows, how much protein you need, and why resistance training is non-negotiable.
GHK-Cu Stinging and Welts: The Copper Peptide Side Effect Most Users Experience
It's not an allergy and it's not a bad batch — it's copper chemistry. Why GHK-Cu is the outlier among peptides, what's happening under your skin, and the dilution-plus-timing fix that actually works.
The CJC-1295/Ipamorelin Flush: Why Your Face Gets Hot After the Shot
Ipamorelin was engineered specifically to eliminate the systemic flush that plagued GHRP-6. So why do users on the CJC/Ipamorelin blend still get warm-faced, tingly, and lightheaded? The answer points squarely at the DAC.
Why So Many People Quit GLP-1 Drugs — And How to Stay on Track
Fewer than 1 in 4 patients stay on GLP-1 medications after a year, and two-thirds of lost weight comes back after stopping. Here's what the data says about why people quit, what happens when they do, and practical strategies for sticking with it.
Tanning Peptides: Melanotan I vs Melanotan II — What the Evidence Actually Shows
One is FDA-approved with 1,000+ patients and zero melanomas. The other is an unlicensed TikTok trend linked to melanoma case reports. They share a name and a receptor — but almost nothing else.
GLP-1 Drugs and Addiction: Can Ozempic Curb Alcohol, Opioids, and More?
A landmark study of 606,000 veterans found GLP-1 drugs reduced new substance use disorders by 14-25% and overdose deaths by 50%. From alcohol to opioids to cannabis, the reward-pathway science is catching up to what patients have been reporting for years.
When Do GLP-1 Patents Expire? The Complete Generic Timeline
Semaglutide patents are already expiring outside the US, generic liraglutide launched in 2025, and tirzepatide is locked up until 2036. Here's when each GLP-1 drug becomes available as a generic — and what that means for cost.
Peptides and Sports: Which Ones Will Get You Banned
From CrossFit to UFC, athletes are catching multi-year bans for peptides like BPC-157, CJC-1295, and TB-500. Here's exactly what WADA prohibits, who's been caught, and what competitive athletes need to know.
The Peptide Quality Crisis: What Investigations Found and How to Protect Yourself
In April 2026, ProPublica, The New Yorker, The Guardian, NBC News, and regulators in three countries converged on the same story: much of what people are injecting isn't what they think it is.
Peptides and the Menstrual Cycle: What Research Shows About Timing, Side Effects, and Hormonal Interactions
GLP-1 nausea is worse when estrogen peaks. GH secretagogue response varies by cycle phase. Kisspeptin sensitivity shifts across the month. Here's what the science says about how peptides interact with the menstrual cycle.
Looksmaxxing Peptides: The Evidence Behind the Aesthetic Optimization Trend
From Retatrutide body recomposition to GHK-Cu skin protocols, peptide stacks have become the backbone of the looksmaxxing movement. We break down what the science actually supports — and where the hype runs ahead of the data.
Peptide Stacking with GLP-1s: What People Are Combining with Ozempic and Mounjaro
GLP-1 drugs work — but muscle loss, GI distress, and skin laxity have people adding BPC-157, GH secretagogues, and more. Here's what the stacking rationale looks like, and where the evidence actually is.
Peptides for Running, Cardio, and Endurance: Recovery, Performance, and What the Evidence Shows
From BPC-157 for tendon injuries to MOTS-c for mitochondrial performance, runners are turning to peptides for an edge. Here's what actually has data behind it — and what's still a bet on animal studies.
Foundayo vs Oral Wegovy: The Battle of the GLP-1 Pills
Eli Lilly's small-molecule pill vs Novo Nordisk's peptide tablet. One is more convenient, the other more effective. Here's what the data shows — and why no head-to-head trial exists yet.
Peptide Injection Site Reactions: Histamine, Mast Cells, and What's Normal
That red, itchy welt after your CJC-1295/Ipamorelin shot isn't an allergy — it's mast cell degranulation, and some peptides trigger it far more than others. Here's the science, the spectrum, and when to actually worry.
Oral vs Injectable Peptides: What Foundayo's Approval Means for the Future
Eli Lilly's oral GLP-1 pill eliminates injections entirely. Here's how oral and injectable peptide delivery compare — and why the future of peptide therapy may be swallowed, not injected.
The Most Popular Peptides of 2026
From oral GLP-1 pills and triple agonists to the FDA reclassification saga and a copper peptide going viral — what's driving 10 million monthly peptide searches.
Will Peptides Work for Me? What Genetics, Sex, and Phenotype Tell Us
A landmark 2026 Nature study of 27,885 people found genetic variants that predict GLP-1 drug response. But genetics is just one piece — here's the full picture of why peptides work differently for different people.
Weight Loss Peptides and Muscle Loss: The Problem, the Science, and How to Protect Lean Mass
GLP-1 drugs produce dramatic fat loss — but 25-40% of weight lost is muscle. New combinations like bimagrumab + semaglutide and next-gen drugs like retatrutide may change that equation.
GLP-1 Drugs and Emotional Flattening: What We Know and Don't Know
Reports of reduced libido, emotional blunting, and 'falling out of love' on semaglutide and retatrutide are growing. The neuroscience is plausible — but the clinical evidence is still early.
Supplements That Stack Well with Peptides: An Evidence-Based Guide
From creatine for GLP-1 muscle preservation to zinc for thymic peptides and magnesium for sleep-stack GH protocols — what the research supports.
Peptide Legality in 2026: FDA Status, Compounding, and the RFK Reclassification
The regulatory landscape for peptides is shifting fast. Here's what's actually changed, what's still pending, and how to legally access peptide therapy in 2026.
Ozempic Alternatives in 2026: Compounded Semaglutide, New Drugs, and What to Know
Brand-name GLP-1 drugs cost $1,000+/month. Here's a research-backed look at compounded semaglutide, tirzepatide, oral options, and what's coming next.
Peptides for Women: What the Research Shows
From FDA-approved sexual health treatments to weight loss, skincare, and fertility — a research-backed look at which peptides have been studied in women and what the evidence says.
Best Peptides for Muscle Growth: What the Evidence Actually Shows
GH secretagogues, IGF-1 variants, and recovery peptides can support lean mass — but the effects are modest compared to steroids. Here's the honest breakdown.
Peptides vs Steroids: A Complete Comparison
Peptides and anabolic steroids are fundamentally different — in mechanism, safety, legality, and what they can realistically achieve. Here's what the evidence shows.
Peptides for Hair Growth: GHK-Cu, TB-500, and What the Research Shows
Copper peptides lead the evidence for peptide-based hair regrowth. Here's what's proven, what's promising, and what's hype.
LL-37 and the Antimicrobial Peptide Frontier
As antibiotic resistance grows, host defense peptides like LL-37 are being studied as a fundamentally different approach to fighting infection.
BPC-157 and Gut Healing: What 30+ Studies Actually Show
The most-cited peptide in the Atlas has a mountain of preclinical data. We break down what's proven, what's promising, and what's still missing.
The Evidence Gap: Which Popular Peptides Have Almost No Human Data?
A frank look at the disconnect between online popularity and clinical evidence for some of the most popular peptides.
GLP-1 Agonists Beyond Weight Loss
What 100+ clinical trials reveal about semaglutide, tirzepatide, and the next generation of incretin therapies — from cardiovascular protection to neurodegeneration.
The Mitochondrial Peptide Revolution
MOTS-c, SS-31, and Humanin are rewriting our understanding of aging at the cellular level. Here's what the research actually shows.
MK-677: The Oral Growth Hormone Secretagogue With 15 RCTs
One of the most studied non-injectable peptide mimetics — what the clinical trial evidence shows about sleep, muscle, bone, and the IGF-1 axis.
Neuropeptides in 2026: Where the Research Actually Stands
Semax, Selank, Cerebrolysin, and Dihexa — separating clinical evidence from online hype in the cognitive enhancement space.
Tesamorelin: From HIV Lipodystrophy to Liver Health and Cognitive Enhancement
How a growth hormone-releasing peptide with 20+ RCTs became one of the most evidence-backed peptides in clinical medicine.
Thymic Peptides and Immune Restoration
Thymosin Alpha-1, Thymalin, and Thymulin — how thymus-derived peptides are being studied to combat immunosenescence and age-related immune decline.